Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis

@article{Mills2005MelatoninIT,
  title={Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis},
  author={Edward J Mills and Ping Wu and Dugald Seely and Gordon H. Guyatt},
  journal={Journal of Pineal Research},
  year={2005},
  volume={39}
}
Most observational studies show an association between melatonin and cancer in humans. [...] Key Method With the aid of an information specialist, we searched 10 electronic databases from inception to October 2004. We included trials using melatonin as either sole treatment or as adjunct treatment. Prespecified criteria guided our assessment of trial quality. We conducted a meta-analysis using a random effects model. We included 10 RCTs published between 1992 and 2003 and included 643 patients.Expand

Paper Mentions

Interventional Clinical Trial
There is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients. This study is designed to see if the daily ingestion of… Expand
ConditionsNon Small Cell Lung Cancer
InterventionDietary Supplement
Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial.
TLDR
Melatonin in combination with chemotherapy did not affect survival and adverse events of advanced patients with NSCLC, but there was a trend for better HRQoL, implying the protective effect of melatonin in healthy cells. Expand
A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes
TLDR
This is the first randomized placebo-controlled study among breast cancer survivors to demonstrate that melatonin was associated with an improvement in subjective sleep quality, without any significant adverse effects. Expand
Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial
TLDR
Adjuvant melatonin following resection of NSCLC does not affect DFS for patients with resected early stage NSCLCs, yet may increase DFS in patients with late stage disease, and no beneficial effects were seen in QOL, symptoms, or immune function. Expand
Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action
TLDR
Melatonin has been shown to be associated with a wide variety of health outcomes in clinically and methodologically heterogeneous populations and many reviews stressed the need for more high-quality randomised clinical trials to reduce the existing uncertainties. Expand
Melatonin for the treatment of dementia
TLDR
The analyses did not support the use of melatonin for treatment of cognitive impairment associated with dementia, and meta-analysis of psychopathologic behavior scale scores suggested that melatonin may be effective in treating these dementia-related disturbances. Expand
Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review
TLDR
There are insufficient robust data to allow a meaningful appraisal of concerns that melatonin may result in more clinically significant adverse effects in potentially at-risk populations, and the scarcity of evidence from long-term RCTs limits the conclusions regarding the safety of continuous melatonin therapy over extended periods. Expand
A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers
TLDR
Overall, among postmenopausal women with a prior history of breast cancer, a 4-month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels, and compliance was comparable between the two groups. Expand
Effects of Melatonin on Quality of Life of Non-resectable Cholangiocarcinoma Patients
TLDR
The combination of melatonin with standard treatment did not prolong overall survival period and the melatonin treatment, however,decreased adverse events and maintained QOL of non-resectable cholangiocarcinoma patients. Expand
Melatonin as Adjuvant Cancer Care With and Without Chemotherapy
TLDR
Melatonin may benefit cancer patients who are also receiving chemotherapy, radiotherapy, supportive therapy, or palliative therapy by improving survival and ameliorating the side effects of chemotherapy. Expand
ARE THE MELATONIN SUPPLEMENTS POTENTIAL TREATMENT OPTIONS? A SYSTEMATIC REVIEW
Introduction: Melatonin is a neuro-hormone secreted from the pineal gland and involved in various regulatory activities in body. Ever-increasing use of melatonin supplements and enlarging researchExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma
TLDR
This preliminary study suggests that an adjuvant endocrine therapy with melatonin may be effective in preventing disease progression in node‐relapsed melanoma patients. Expand
Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group
TLDR
The reporting of methodological aspects of randomised controlled trials does not necessarily reflect the conduct of the trial and reviewing research protocols and contacting trialists for more information may improve quality assessment. Expand
Is there a role for melatonin in the treatment of neoplastic cachexia?
TLDR
It is suggested that the pineal hormone MLT may be effective in the treatment of the neoplastic cachexia by decreasing TNF blood concentrations. Expand
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
TLDR
This randomized study shows that the pineal hormone MLT may be successfully administered to prolong the survival time in metastatic NSC lung cancer patients who progressed under a first-line chemotherapy with cisplatin, for whom no other effective therapy is available up to now. Expand
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
TLDR
The neuroendocrine combination with TMX plus MLT may have some benefit in untreatable metastatic solid tumour patients, either in controlling cancer cell proliferation or improving the PS. Expand
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.
TLDR
This preliminary study suggests that the association of the pineal hormone MLT may make TMX effective also in ER-negative metastatic breast cancer patients. Expand
Five years survival in metastatic non‐small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial
TLDR
Assessment of the 5‐year survival results in metastatic non‐small cell lung cancer patients obtained with a chemotherapeutic regimen consisting of cisplatin and etoposide, with or without the concomitant administration of melatonin suggests a new biochemotherAPEutic strategy in the treatment of human neoplasms. Expand
Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care.
TLDR
Application of the technique to the randomized control trials of streptokinase treatment of acute myocardial infarction, reduction of peri-operative mortality by antibiotic prophylaxis, and prevention of death from bleeding peptic ulcers has revealed efficacy years before it was suspected by any other means. Expand
Melatonin in cancer patients and in tumor-bearing animals.
TLDR
Clinical and experimental findings relating to melatonin are discussed both in terms of their practical application as a possible tumor marker and from a theoretical point of view to understand better the mechanisms involved in complex host-tumor interactions involving the neuroimmunoendocrine network. Expand
Anti-angiogenic activity of melatonin in advanced cancer patients.
TLDR
Melatonin-induced control or the neoplastic growth is associated with a decline in VEGF secretion, which would suggest that the pineal hormone may control tumor growth at least in part by acting as a natural anti-angiogenic molecule, with a following opposition or angiogenesis-dependent cancer proliferation. Expand
...
1
2
3
4
5
...